Dendreon (DNDN): How high will it go?

Now that Provenge, the prostate cancer drug from Dendreon (DNDN) got past FDA Phase 3 approval, what's next?

The stock jumped from under $30/share to $40/share from January 2010 to April 2010.

Then yesterday, the good news hit, and the stock closed at $50/share, and pre-market indicators already push it higher, yet.

Last year, I read an article that predicted that the stock could go as high as $220. I think THAT might be an optimistic estimate, but this drug addresses something that strikes fear in even the toughest of men--prostate cancer. Prostate cancer ain't no joke! In fact, some evidence points to every man being guaranteed to get it sometime in his life IF he lives long enough. So that's a heck of a market.

Add to that fact that Provenge reportedly is less painful and prolongs life for about four (4) months.

Dendreon does not have any other drugs on the market; it's a one-trick pony. Maybe it learns to become a master marketer. More likely, one of the bigger players will buy out Dendreon to add the drug to its lineup.

There are lots of questions, but only one matters: How high can Dendreon stock go?